09 Dec Amphivena Reports Data on Phase 1 Study of AMV564 at ASH Annual Meeting
[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] South San Francisco, CA – (Business Wire) -- Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, presented today at the American Society of Hematology annual meeting data from a Phase...